HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hepatitis

INFLAMMATION of the LIVER.
Also Known As:
Hepatitides
Networked: 25722 relevant articles (1007 outcomes, 2036 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Infections
2. Fibrosis (Cirrhosis)
3. Hepatitis B
4. Liver Diseases (Liver Disease)
5. Chronic Hepatitis (Chronic Active Hepatitis)

Experts

1. Kumada, Hiromitsu: 35 articles (05/2014 - 01/2002)
2. Liaw, Yun-Fan: 33 articles (10/2022 - 01/2002)
3. Tanaka, Yasuhito: 33 articles (09/2022 - 08/2004)
4. Gao, Bin: 32 articles (01/2021 - 02/2002)
5. Suzuki, Yoshiyuki: 32 articles (04/2018 - 01/2002)
6. Kao, Jia-Horng: 31 articles (06/2021 - 01/2003)
7. Chen, Pei-Jer: 30 articles (01/2022 - 10/2002)
8. Manns, Michael P: 29 articles (01/2021 - 02/2002)
9. Suzuki, Fumitaka: 29 articles (01/2014 - 01/2002)
10. Mizokami, Masashi: 28 articles (05/2021 - 11/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Hepatitis:
1. InterferonsIBA
2. Antiviral Agents (Antivirals)IBA
3. Hepatitis B Surface Antigens (HBsAg)FDA Link
4. VaccinesIBA
5. Interferon-alpha (Interferon Alfa)IBA
6. Concanavalin AIBA
7. AntigensIBA
8. Lamivudine (Epivir)FDA Link
9. Hepatitis B e AntigensIBA
01/01/1998 - "Therefore, in patients with CH-B who had a sustained loss of HBeAg and complete remission of hepatitis after SC, the precore region was sequenced in paired serum samples from 1 year before SC to 3 years after SC. "
02/01/1984 - "Episodes of reactivation invariably occurred within 1 yr of loss of hepatitis B e antigen and lasted for up to 13 mo. These observations suggest that loss of hepatitis B e antigen and seroconversion to the antibody to hepatitis B e antigen do not necessarily imply permanent remission of chronic type B hepatitis, and subsequent spontaneous reactivation may be an important cause of progression of hepatic injury."
08/01/1996 - "Although IFN was effective in controlling the manifestations of hepatitis in terms of e-antigen-negative patients who exhibited abnormal fluctuations in ALT, it appears that continuous treatment with intermittent high-dose IFN is necessary to maintain ALT levels within the normal range."
12/01/2002 - "Seroconversion to antibody to hepatitis B e antigen (anti-HBe) was unrelated to HBV genotype, but the rate of sustained remission after seroconversion was higher in genotype A than in genotype D hepatitis both in patients who seroconverted to anti-HBe during follow-up (log-rank, 4.5; P = 0.03) and in patients with positive anti-HBe at baseline (log-rank, 6.66; P = 0.009). "
01/01/1995 - "These results are consistent with the hypothesis that after clearance of HBeAg, mutations in regions of the virus recognized by CD4+ helper T cells and B cells allow persistence of the HBe negative virus in HBeAb positive patients with viraemia and active hepatitis."
10. DNA (Deoxyribonucleic Acid)IBA

Therapies and Procedures

1. Therapeutics
2. Liver Transplantation
3. Drug Therapy (Chemotherapy)
4. Transplantation
5. Blood Transfusion (Blood Transfusions)